Aileron Therapeutics Garners $12,000,000 Series D Financing

  • Feed Type
  • Date
    1/14/2013
  • Company Name
    Aileron Therapeutics
  • Mailing Address
    281 Albany St. Cambridge, MA 02139
  • Company Description
    Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
    for the treatment of cancer and other diseases. Aileron’s technology is the first and
    only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs.
  • Website
    http://www.aileronrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from this tranche will be directed to the clinical development of ALRN-5281 in patients with orphan endocrine disorders early this year. Initiation of the ALRN-5281 clinical trial will mark the first-ever Stapled Peptide human clinical trial.
  • M&A Terms
  • Venture Investor
    Apple Tree Partners
  • Venture Investor
    Excel Venture Management
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    SR One

By posting a comment, you agree to our terms and conditions.